Seeking Alpha

AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira...

AstraZeneca's (AZN -1.6% in London) fostamatinib pill was inferior to Abbott Labs' (ABT) Humira in controlling rheumatoid arthritis symptoms in a Phase II trial. AstraZeneca can still pin its hopes, though, on a Phase III study in which fostamatinib is being given with other drugs. Results are due out in H1 next year. (PR)
Comments (1)
  • Bellevue1950
    , contributor
    Comment (1) | Send Message
     
    Comparing an oral agent with injection.

     

    This Astradrug can still be a marketwinner as an ad on to
    other orals.
    The marketreaction is not motivated
    17 Dec 2012, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs